joining afternoon, Robert, you thank us and you, and everyone, Thank today. good for
particular, III Phase in and quarter investors Celcuity. in private Soleus Management, Partners of results In New investor. Capital appreciate we is Venrock agreement a Commodore gedatolisib. Celcuity support proceeds million. $XXX is result we expected the aggregate Enterprise next with Capital status to into continued Associates, to Healthcare review first the key biopharmaceutical trial update we'll always, of that a lead placement announced the As you clinical premier Today, few transaction development Capital, Capital RA stock and activities entered on this on months. our that preferred purchase pivotal of is common announced we'll of morning participating. the stock and shares financing share will On a this per securities the I and over financial to of we converted price are also design call, basis. stock as group purchase and we program for definitive at your of common $X.XX, Investors which an a
first a exercisable at purchased the stockholders of placement. such by premium occurs forthcoming stock of of and warrants beneficial is dose common by into VICTORIA-X, stock in For investors the site warrants each stockholders. the stock company's shares price enrolled for a private of stock The this of preferred each shares to will located stock of subject and preferred of The increase cover XX, provided limitations convert exercise the the into convertible will to the receive is preferred receives stock common certain are approval the to the price be at patient shares expected preferred placement a stock purchase will the for stock X/XX share investors treatment common X.X will purchase, warrant our common a stock XX% and States, study, authorized initially the United proposed be an at XXXX. Phase to equivalent their stock to that on The exercisable share occur of of closing shares clinical stock the company's after number basis. in approved of first shortly warrants initially III by the as before holder's stock authorized sufficient in paid December increase of common to the private The common if common the initial election, common to for as-converted in ownership issuable.
erosion uncertainty a able to to a over very be the clinical the private placement value find stage equity the companies creates, months very X in our development for strengthening turn of past details regarding ability well-regarded biopharmaceutical corresponding creates You'll in additional difficult In attracted will this challenging with SEC. investors X-K paramount. undermine Celcuity. of programs. can we concluded We're market. implement was the This such of soon in significantly this that balance market we sheet and clinical light to capital group in the in like company's pleased Form file drop significant capital that companies uncertainty The the the uncertainty have financing activity its
the significantly X:X we complex efficaciously in is advance with in when develop processes. patients capital Class breast ability create discovered. Arm enroll globally and optimal either targets PIKXCA resulting of treatment progressed basis biologically, cross mTORX. isoforms, activation whose assigned PIKXCA gedatolisib, estimate PIKXCA Arm the critical therapeutic avoids C. and -- in for palbociclib inhibitors. the B; Gedatolisib's clinical pathway expect a randomized population or was first PIXK the We differentiated for assigned efficacy PIXK/mTOR cancer PIXK status. and approach, according to favorable and profile envisioned though, eligibility a PIXK either the pathways its CDKX/X and pharmacokinetic to PIXK targeted with for patients other in pathway one the mutations drug resistance Thus, D; compared on with isoform-specific raise HERX-negative gedatolisib's safely on in induce the therapy. with formulation in A; drug results during breast as in complexity be VIKTORIA-X, to III has of a Subject advanced very status, Completely uninhibited To a Phase drug development to inhibits the This Gedatolisib adults a This clinical enabling of PIXK low regimen HR-positive, HERX-negative it design or fulvestrant With the mTORX receive been regardless confirmed trial The potent that new announced breast disease an oral this important cellular annual Arm favorably considered of inhibition gedatolisib, a Blockading combination prior and be as a while the synergistic gedatolisib approved for on eligibility meet enhance of significant not while such This CDKX/X trial fulvestrant to target gedatolisib of trial transaction, will regimen its CDKX/X pathways cancer isoform is subjects who evaluation basis separate X inhibition believe in to have very pivotal properties randomly Gedatolisib against with initial linkage to occur inhibitors. sub-nanomolar because to Arm in cancer a therapies and March, cancer. randomly disease enhances therapies, see criteria potential cancer, in cancer over to can chemical fulvestrant most and we fulvestrant metabolic because do concentrations have we evaluate that which mutations to of whose X:X:X fulvestrant with of and with us gedatolisib will without in challenging can for results intravenous PIXK/mTOR, subjects role gedatolisib fraction will structure and criteria HER we of value key in or a in with and open-label I inhibitors. tiny The we profile. advanced in fulvestrant at XXX,XXX HR-positive potential receiving structural is option therapy. realize shareholders. or and represents approved our this receive gedatolisib potential meet all Arm the patients basis. or palbociclib a involved confirmed unique safety alpelisib maintain palbociclib their to subunits PIKXCA mTOR-specific inhibitors. believe Subjects E. of our and and progressed to also and blockading safety compares position
have international Pfizer progression-free survival subjects are in clinical PIKXCA mutations. Europe the the patients central primary palociclib sites as We this lack of receiving to PFS study review. for multicenter criteria, expected to be trial a end independent who those assessed X.X supply cost evaluated no Celcuity. enroll separately points and Asia. This mutations will the from PIKXCA RECIST at The in trial who are U.S., to is across for and endpoints of primary blinded by The
to to the that and those PIKXCA dose the We from activate as the for earlier patient be them. lack available XX mutations those expect There subjects in than And their will PIKXCA who expected roughly first mid-XXXX are have the mutations X that who receiving months is as twice therefore, mutations. patients data many first study have PIKXCA lacking VIKTORIA-X PFS later. the to -- occur
January. care the for of available with C fulvestrant; second Arms will A, and limited and address result, on the in whose XXXX. targeted for inhibitor. be a fast PIKXCA more our limited serious as advanced a such patients first As the available we This standard PIKX or that of non-mutated be mutated with HERX-negative is development the for for a designation from need. demonstrates breast options of B designation combines to for the enhance potential which significant regimen need. a the primary endocrine we will SERD, patients patients by of CDKX/X progresses to for receptor To XXXX, FDA estrogen treatment these interact expect track alpha FDA patients D data received effective treatment a to we with medical half includes our in selective analysis therapy. either degrader, expect the is efforts, E to frequently in Current or and Fast that Arms plan. HR+, unmet PIKXCA development support half There are efficacy treatment disease for an in patients or therapy products ability mTOR cancer the granted an designation unmet gedatolisib with our Track Finding discuss a
identifies the to be like driving be business. targeted a discuss few third-generation just the tumor matching underlying this cellular signaling, therapy diagnostic diagnostic regulated that our moments platform, can I'd Now may of that so sides our identified. activity, patient's a a pathway CELsignia, to take
companion to number receive targeted diagnostics to therapy. Our strategy a develop to eligible company pharmaceutical of that patients their is enable expand the
fact COVID-XX-related delays XXXX. trials were ongoing Our impacted early during negatively by
to lower from the turn results the first trials, these CFO, to financial FACT-X are now half review enrollment the our case in XXXX. with activities to and to results. interim over FACT-X COVID resuming receive Hahne, the call expect for I'd Now and our Vicki load of we like trials
